|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Valeant Pharmaceuticals International changed its name to Bausch Health (BHC), but Piper Jaffray's David Amsellem thinks the stock is a sell no matter what you call it. Amsellem reiterated an Underweight rating on Bausch on Monday, writing that the while the name change "refreshingly consigns the Valeant name to the dustbin of pharma history," and while that may help the company put some missteps behind it, he still has "myriad concerns regarding the commercial portfolio and pipeline." He writes that it's still too soon to say when and where Bausch's earnings before interest, taxes, depreciation and amortization will trough. The recent tentative approval of a generic form of the non-steroid anti-inflammatory drug Apriso only serves to further highlight the company's "significant exposure to loss of exclusivities." Moreover, Amsellem writes that data points about new drug launches, specifically inflammatory treatment Siliq and eye drug Vyzulta "are suggestive of underwhelming traction." Given this, along with the company's exposure to mature assets with "questionable durability and leverage ratios that are still very much an eyesore" he thinks Bausch's valuation of 10 times enterprise value to Ebitda is still too high.
A strong first-quarter sent the pharmaceutical company's shares northward, but this positive momentum is starting to fade after a key regulatory setback.
Valeant Pharmaceuticals (VRX), now known as Bausch Health Companies (BHC), generated revenues of $2 billion in the first quarter compared to $2.1 billion in the first quarter of 2017, reflecting a 5% YoY (year-over-year) decline.
In July, the FDA accepted Bausch + Lomb’s NDA (New Drug Application) for sub-micron loteprednol etabonate for the treatment of patients who have undergone ocular surgery and are showing symptoms of post-operative inflammation and pain.
Investors in Valeant Pharmaceuticals (VRX) need to pay close attention to the stock based on moves in the options market lately.
NEW YORK, NY / ACCESSWIRE / July 9, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with ...
Why investors ought not to be dissuaded by an FDA rejection for a key Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) psoriasis cream.
Here's a company that may make a splash in the cannabis-based pharmaceuticals space, and it's not a producer like Canopy Growth Corp. (TSX:WEED)!
A controversy over massive price increases, along with other scandals, wrecked Valeant Pharmaceutical International Inc.’s reputation as well as its stock price in recent years. Valeant (VRX) is using two techniques to raise prices on one of its best-selling drugs: it has increased the size of the package of its diarrhea medication, called Xifaxan, by 43%, from 42 pills to 60, and it is charging about 6% more per milligram, according to an analyst note by Mizuho’s Irina Koffler. The larger packaging has helped boost sales volumes, Koffler said.
Learn how your own psychological makeup can provide valuable insights as to whether a stock like Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is the right fit for you.
Shares of Valeant Pharmaceuticals International (VRX) sold off earlier this month after the company received a Complete Response Letter from the Food and Drug Administration concerning its plaque psoriasis Duobrii. However, Mizuho's Irina Koffler argues that the selloff is overdone, as she believes that Xifaxan, the traveler's diarrhea and irritable-bowel-syndrome treatment, is Valeant's key growth driver, rather than its dermatology portfolio. She reiterated a Buy rating on Valeant Friday and raised her price target by $4 to $31. The SPDR S&P Pharmaceuticals ETF (XPH) is up 0.5% to $43.18 and the Health Care Select Sector SPDR ETF (XLV) is up 0.8% to $83.92.
Find out what you can do to keep yourself from staying up at night wondering about what companies like Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) are doing with your hard-earned money.
Leverage can be both a gift and a curse. Find out what makes the cases of Dollarama Inc. (TSX:DOL) and Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) so different.
Valeant Pharmaceuticals (VRX) stock has been falling in June. Valeant’s division Ortho Dermatologics received a CRL (complete response letter) from the FDA on June 18 for its new drug application for Duobril, which treats plaque psoriasis. Valeant’s Siliq, which treats moderate to severe psoriasis, received FDA approval earlier.
BlackBerry Ltd. (TSX:BB)(NYSE:BB) and Bombardier, Inc. (TSX:BBD.B) are two turnaround stocks that investors should consider as growth drivers for 2018 and beyond.
Aurora Cannabis Inc. (TSX:ACB) is a strong buy on the dip. Here's why the shareholder-dilutive acquisitions may not be as insidious as investors believe them to be.
Jim Cramer shares his take on callers' favorite stocks at lightning speed, including a much debated social media play.
In 2015, Cindy Eckert (then Whitehead) made headlines after landing a billion-dollar deal for the company she co-founded, Sprout Pharmaceuticals, which developed female libido-boosting drug Addyi. Eckert co-founded Sprout Pharmaceuticals with her then-husband Robert Whitehead in 2011 to acquire a medication called flibanserin. With it, Sprout developed Addyi, dubbed "female Viagra," to treat hypoactive sexual desire disorder in premenopausal women ( 10 percent of all women suffer from HSDD).
Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) may have hit a stumbling block with one of the Significant Seven, but long-term investors should stay the course.